Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

XLV vs. ETHSX: which is better?

Bottom line

XLV vs ETHSX: the short answer

XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and ETHSX (Eaton Vance Worldwide Health Sciences Fund) share a meaningful slice of their top holdings — about 63% by weight.

XLV is cheaper at 0.08% vs 1.18% — a difference of $110 a year per $10,000 invested.

Over five years, XLV returned +8.1% a year vs +5.3% for ETHSX (reporting dates differ).

ETHSX has a front-end sales load of up to 5.25%; the other does not.

Updated Nov 19, 2026

XLV vs ETHSX side by side

XLVETHSX
TypeETFMutual fund
Fund familySPDR (State Street)Morgan Stanley
CategoryHealth Care SectorHealth Care Sector
Expense ratio0.08%1.18%
Annual cost per $10k$8$118
10-yr cost on $10k (prospectus)$103$1,911
Max front loadNone5.25%
12b-1 fee0.02%0.25%
1-yr return+14.5%−1.9%
5-yr return (annualized)+8.1%+5.3%
10-yr return (annualized)+9.8%+6.4%
Best quarter+14.5%+14.2%
Worst quarter−12.7%−12.1%
Net assets (fund)$40.6B$757.9M
Number of holdings6542
Portfolio turnover2%3%
Returns as ofDec 31, 2025Dec 31, 2024

Source: SEC Form N-PORT and fund prospectuses

Year-by-year returns

YearXLVETHSXDifference
2024+2.5%+3.5%−1.0%
2023+2.0%+5.7%−3.7%
2022−2.1%−9.4%+7.4%
2021+25.9%+22.1%+3.9%
2020+13.3%+13.0%+0.2%
2019+20.7%+26.0%−5.3%
2018+6.3%+6.0%+0.3%
2017+21.7%+16.2%+5.5%
2016−2.8%−14.9%+12.1%

Source: Fund prospectus bar charts

Holdings overlap

14 of XLV's top 25 holdings also appear in ETHSX's top 25.

Shared top holdings
HoldingXLVETHSX
Eli Lilly & Co16.51%12.47%
Johnson & Johnson10.64%6.45%
AbbVie Inc7.74%6.46%
UnitedHealth Group Inc6.57%5.49%
Merck & Co Inc5.52%5.08%
Thermo Fisher Scientific Inc3.24%2.79%
Abbott Laboratories2.75%1.65%
Gilead Sciences Inc2.73%3.34%
Intuitive Surgical Inc2.45%2.72%
Vertex Pharmaceuticals Inc2.19%3.38%
Bristol-Myers Squibb Co2.05%4.25%
Stryker Corp1.89%2.21%
Medtronic PLC1.75%1.80%
Boston Scientific Corp1.10%2.18%

Source: SEC Form N-PORT

XLV top 10

  1. Eli Lilly & Co — 16.51%
  2. Johnson & Johnson — 10.64%
  3. AbbVie Inc — 7.74%
  4. UnitedHealth Group Inc — 6.57%
  5. Merck & Co Inc — 5.52%
  6. Amgen Inc — 3.40%
  7. Thermo Fisher Scientific Inc — 3.24%
  8. Abbott Laboratories — 2.75%
  9. Gilead Sciences Inc — 2.73%
  10. Intuitive Surgical Inc — 2.45%

ETHSX top 10

  1. Eli Lilly & Co — 12.47%
  2. AbbVie Inc — 6.46%
  3. Johnson & Johnson — 6.45%
  4. AstraZeneca PLC — 6.24%
  5. UnitedHealth Group Inc — 5.49%
  6. Roche Holding AG — 5.44%
  7. Merck & Co Inc — 5.08%
  8. Bristol-Myers Squibb Co — 4.25%
  9. Vertex Pharmaceuticals Inc — 3.38%
  10. Gilead Sciences Inc — 3.34%

FAQ

What is the difference between XLV and ETHSX?
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and ETHSX (Eaton Vance Worldwide Health Sciences Fund) share a meaningful slice of their top holdings — about 63% by weight. XLV is cheaper at 0.08% vs 1.18% — a difference of $110 a year per $10,000 invested.
Which is cheaper, XLV or ETHSX?
XLV has the lower expense ratio (0.08%).
Should I own both XLV and ETHSX?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.

Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.